A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Clinical trial NCT05655520 · TERMINATED

Trial details

NCT number: NCT05655520
Sponsor: Supernus Pharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Huntington's Disease

Start date: 2022-12-14
Primary completion: 2025-01-20
Enrollment: 153

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.